FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Su Zhen				<u>C</u> y	2. Issuer Name and Ticker or Trading Symbol  CytomX Therapeutics, Inc. [ CTMX ]							eck all applic	tor 10% Ov		vner	
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 03/20/2024							below)	(give title	Other (sbelow)	specify
C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person				
(Street) SOUTH FRANCI		A	94080			ر مار	10hE :	1(0)	Transa	ation In	diaatiaa		Form f Persor		han One Repo	rting
(City)		tate)	(Zip)			Chec	k this box	to indi	Transa	nsaction was	made pursua	ant to a conti		n or written pla	n that is intende	d to
		Tab	le I - Non-	-Deriv	ativ	e Sec	curities	s Ac	quired, D	isposed	of, or Be	neficial	y Owned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D.					Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year		e, Transaction Disposed Code (Instr. 5)		rities Acquired (A) or ad Of (D) (Instr. 3, 4 an		Beneficia Owned F	es Formally (D) of Following (I) (II)	orm: Direct	7. Nature of Indirect Beneficial Ownership
								Code	Amoun	(A) o	r Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)	
		7	Γable II - D (€						uired, Dis , options				Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)  3. Deemed Execution Di if any (Month/Day/Year)	Date, Transaction Code (Ins.					6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$2.27	03/20/2024			Α		76,000		(1)	03/19/2034	Common Stock	76,000	\$0	76,000	D	

## **Explanation of Responses:**

1. 1/36th of the shares subject to the option vest on each monthly anniversary measured from March 20, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

/s/ Lloyd Rowland, as
Attorney-in-Fact for Zhen Su
\*\* Signature of Reporting Person

. .

03/22/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).